{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:14:30Z","timestamp":1779358470783,"version":"3.51.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation Key Project","award":["LZ22H270001"],"award-info":[{"award-number":["LZ22H270001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-026-02321-w","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:06:03Z","timestamp":1776150363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in research on circadian rhythms and colorectal cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Lingjuan","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaqiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"2321_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.canlet.2021.09.034","volume":"522","author":"N Li","year":"2021","unstructured":"Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255\u201368.","journal-title":"Cancer Lett"},{"issue":"3","key":"2321_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2321_CR3","unstructured":"Hospital Authority of National Health Commission of the People's Republic of China, Chinese Society of Oncology Chinese Medical Association. Chinese Colorectal Cancer Diagnosis and Treatment Standards (2023 Edition). Journal of digestive oncology (electronic version). 2023;15(03):177\u2013206."},{"issue":"7551","key":"2321_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/521S1a","volume":"521","author":"H Brody","year":"2015","unstructured":"Brody H. Colorectal cancer. Nature. 2015;521(7551):S1.","journal-title":"Nature"},{"issue":"23","key":"2321_CR5","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1001\/jama.2016.5989","volume":"315","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garc\u00eda FAR, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(23):2564\u201375.","journal-title":"JAMA"},{"key":"2321_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ebiom.2019.07.004","volume":"45","author":"E Burgermeister","year":"2019","unstructured":"Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, et al. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL\/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine. 2019;45:139\u201354.","journal-title":"EBioMedicine"},{"key":"2321_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ebiom.2019.08.003","volume":"46","author":"D Della-Morte","year":"2019","unstructured":"Della-Morte D. Deregulation of the circadian clock machinery: a novel biomarker for anti-angiogenic drug resistance in colorectal cancer. EBioMedicine. 2019;46:17\u20138.","journal-title":"EBioMedicine"},{"issue":"4","key":"2321_CR8","doi-asserted-by":"publisher","first-page":"e13875","DOI":"10.1111\/jsr.13875","volume":"32","author":"J \u0160mon","year":"2023","unstructured":"\u0160mon J, Ko\u010dar E, Pintar T, Dolenc-Gro\u0161elj L, Rozman D. Is obstructive sleep apnea a circadian rhythm disorder? J Sleep Res. 2023;32(4):e13875.","journal-title":"J Sleep Res"},{"key":"2321_CR9","unstructured":"Zhu K, Zhang T. Research progress on the correlation between circadian rhythm disorders and neurodegenerative degenerative diseases. Nerve Inj Funct Reconstr. 2023;18(09):522\u20135."},{"issue":"2","key":"2321_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.tcb.2013.07.002","volume":"24","author":"CL Partch","year":"2014","unstructured":"Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian circadian clock. Trends Cell Biol. 2014;24(2):90\u20139.","journal-title":"Trends Cell Biol"},{"key":"2321_CR11","doi-asserted-by":"crossref","unstructured":"Man AWC, Li H, Xia N. Circadian Rhythm: Potential Therapeutic Target for Atherosclerosis and Thrombosis. Int J Mol Sci. 2021;22(2):1422\u20130067.","DOI":"10.3390\/ijms22020676"},{"key":"2321_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2017.01.012","volume":"390","author":"E Reszka","year":"2017","unstructured":"Reszka E, Przybek M, Muurlink O, Pep\u0142onska B. Circadian gene variants and breast cancer. Cancer Lett. 2017;390:137\u201345.","journal-title":"Cancer Lett"},{"issue":"12","key":"2321_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/mc.20446","volume":"47","author":"YM Lin","year":"2008","unstructured":"Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008;47(12):925\u201333.","journal-title":"Mol Carcinog"},{"issue":"1","key":"2321_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1083\/jcb.201603076","volume":"215","author":"A Chaix","year":"2016","unstructured":"Chaix A, Zarrinpar A, Panda S. The circadian coordination of cell biology. J Cell Biol. 2016;215(1):15\u201325.","journal-title":"J Cell Biol"},{"issue":"8","key":"2321_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 2019;5(8):475\u201394.","journal-title":"Trends Cancer"},{"issue":"3","key":"2321_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/1567202614666170718092010","volume":"14","author":"K Maiese","year":"2017","unstructured":"Maiese K. Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer. Curr Neurovasc Res. 2017;14(3):299\u2013304.","journal-title":"Curr Neurovasc Res"},{"issue":"4","key":"2321_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3109\/07853890.2014.914808","volume":"46","author":"NM Kettner","year":"2014","unstructured":"Kettner NM, Katchy CA, Fu L. Circadian gene variants in cancer. Ann Med. 2014;46(4):208\u201320.","journal-title":"Ann Med"},{"key":"2321_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/B978-0-12-396971-2.00009-9","volume":"119","author":"L Fu","year":"2013","unstructured":"Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci. 2013;119:221\u201382.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"32","key":"2321_CR19","doi-asserted-by":"publisher","first-page":"eabo2389","DOI":"10.1126\/sciadv.abo2389","volume":"8","author":"SK Chun","year":"2022","unstructured":"Chun SK, Fortin BM, Fellows RC, Habowski AN, Verlande A, Song WA, et al. Disruption of the circadian clock drives Apc loss of heterozygosity to accelerate colorectal cancer. Sci Adv. 2022;8(32):eabo2389.","journal-title":"Sci Adv"},{"key":"2321_CR20","doi-asserted-by":"crossref","unstructured":"Rao X, Lin L. Circadian clock as a possible control point in colorectal cancer progression (Review). Int J Oncol. 2022;61(6):1791\u20132423.","DOI":"10.3892\/ijo.2022.5439"},{"issue":"1","key":"2321_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11033-021-06883-z","volume":"49","author":"P Dong","year":"2022","unstructured":"Dong P, Wang Y, Liu Y, Zhu C, Lin J, Qian R, et al. BMAL1 induces colorectal cancer metastasis by stimulating exosome secretion. Mol Biol Rep. 2022;49(1):373\u201384.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"2321_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ijc.27760","volume":"132","author":"M Sot\u00e1k","year":"2013","unstructured":"Sot\u00e1k M, Polidarov\u00e1 L, Ergang P, Sumov\u00e1 A, P\u00e1cha J. An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. Int J Cancer. 2013;132(5):1032\u201341.","journal-title":"Int J Cancer"},{"issue":"4","key":"2321_CR23","doi-asserted-by":"publisher","first-page":"G629","DOI":"10.1152\/ajpgi.2001.280.4.G629","volume":"280","author":"SS Rao","year":"2001","unstructured":"Rao SS, Sadeghi P, Beaty J, Kavlock R, Ackerson K. Ambulatory 24-h colonic manometry in healthy humans. Am J Physiol Gastrointest Liver Physiol. 2001;280(4):G629\u201339.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"2321_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1053\/j.gastro.2007.05.053","volume":"133","author":"M Sl\u00e1dek","year":"2007","unstructured":"Sl\u00e1dek M, Rybov\u00e1 M, Jindr\u00e1kov\u00e1 Z, Zemanov\u00e1 Z, Polidarov\u00e1 L, Mrnka L, et al. Insight into the circadian clock within rat colonic epithelial cells. Gastroenterology. 2007;133(4):1240\u20139.","journal-title":"Gastroenterology"},{"issue":"1","key":"2321_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/gut.28.1.17","volume":"28","author":"F Narducci","year":"1987","unstructured":"Narducci F, Bassotti G, Gaburri M, Morelli A. Twenty four hour manometric recording of colonic motor activity in healthy man. Gut. 1987;28(1):17\u201325.","journal-title":"Gut"},{"issue":"3","key":"2321_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.molcel.2006.03.038","volume":"22","author":"S Gery","year":"2006","unstructured":"Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22(3):375\u201382.","journal-title":"Mol Cell"},{"issue":"7","key":"2321_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3109\/07420520903431301","volume":"26","author":"X Yang","year":"2009","unstructured":"Yang X, Wood PA, Ansell CM, Quiton DF, Oh EY, Du-Quiton J, et al. The circadian clock gene PER1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009;26(7):1323\u201339.","journal-title":"Chronobiol Int"},{"issue":"4","key":"2321_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2443.2010.01384.x","volume":"15","author":"K Miyazaki","year":"2010","unstructured":"Miyazaki K, Wakabayashi M, Hara Y, Ishida N. Tumor growth suppression in vivo by overexpression of the circadian component, PER2. Genes Cells. 2010;15(4):351\u20138.","journal-title":"Genes Cells"},{"issue":"3","key":"2321_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/jb\/mvn167","volume":"145","author":"X Yang","year":"2009","unstructured":"Yang X, Wood PA, Ansell CM, Ohmori M, Oh EY, Xiong Y, et al. -catenin induces -TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin\/+ mice. J Biochem. 2009;145(3):289\u201397.","journal-title":"J Biochem"},{"key":"2321_CR30","unstructured":"He Yiyang. Expression and clinical significance of PER3 and Notch1 in human colorectal adenocarcinoma tissues Zunyi Medical College. 2018."},{"issue":"5","key":"2321_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3892\/or.2011.1207","volume":"25","author":"T Oshima","year":"2011","unstructured":"Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep. 2011;25(5):1439\u201346.","journal-title":"Oncol Rep"},{"issue":"5","key":"2321_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3727\/096504016X14772331883976","volume":"25","author":"F Zhang","year":"2017","unstructured":"Zhang F, Sun H, Zhang S, Yang X, Zhang G, Su T. Overexpression of PER3 Inhibits Self-Renewal Capability and Chemoresistance of Colorectal Cancer Stem-Like Cells via Inhibition of Notch and \u03b2-Catenin Signaling. Oncol Res. 2017;25(5):709\u201319.","journal-title":"Oncol Res"},{"issue":"5","key":"2321_CR33","first-page":"5319","volume":"14","author":"T Momma","year":"2017","unstructured":"Momma T, Okayama H, Saitou M, Sugeno H, Yoshimoto N, Takebayashi Y, et al. Expression of circadian clock genes in human colorectal adenoma and carcinoma. Oncol Lett. 2017;14(5):5319\u201325.","journal-title":"Oncol Lett"},{"issue":"7","key":"2321_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1541-7786.MCR-10-0086","volume":"8","author":"P Alhopuro","year":"2010","unstructured":"Alhopuro P, Bj\u00f6rklund M, Sammalkorpi H, Turunen M, Tuupanen S, Bistr\u00f6m M, et al. Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res. 2010;8(7):952\u201360.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"2321_CR35","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cncr.26348","volume":"118","author":"F Zhou","year":"2012","unstructured":"Zhou F, He X, Liu H, Zhu Y, Jin T, Chen C, et al. Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer. 2012;118(4):937\u201346.","journal-title":"Cancer"},{"issue":"1","key":"2321_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jcmgh.2021.02.008","volume":"12","author":"JL Liu","year":"2021","unstructured":"Liu JL, Wang CY, Cheng TY, Rixiati Y, Ji C, Deng M, et al. Circadian clock disruption suppresses PDL1+ intraepithelial B cells in experimental colitis and colitis-associated colorectal cancer. Cell Mol Gastroenterol Hepatol. 2021;12(1):251\u201376.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"9","key":"2321_CR37","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/sj.bjc.6601338","volume":"89","author":"D Arango","year":"2003","unstructured":"Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C, et al. C-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer. 2003;89(9):1757\u201365.","journal-title":"Br J Cancer"},{"issue":"4","key":"2321_CR38","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1002\/cam4.5129","volume":"12","author":"L Shan","year":"2023","unstructured":"Shan L, Zheng W, Bai B, Hu J, Lv Y, Chen K, et al. BMAL1 promotes colorectal cancer cell migration and invasion through ERK- and JNK-dependent c-Myc expression. Cancer Med. 2023;12(4):4472\u201385.","journal-title":"Cancer Med"},{"key":"2321_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2018.07.002","volume":"33","author":"L Fuhr","year":"2018","unstructured":"Fuhr L, El-Athman R, Scrima R, Cela O, Carbone A, Knoop H, et al. The circadian clock regulates metabolic phenotype rewiring via HKDC1 and modulates tumor progression and drug response in colorectal cancer. EBioMedicine. 2018;33:105\u201321.","journal-title":"EBioMedicine"},{"issue":"7","key":"2321_CR40","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1080\/07420528.2018.1477792","volume":"36","author":"MJ Qiu","year":"2019","unstructured":"Qiu MJ, Liu LP, Jin S, Fang XF, He XX, Xiong ZF, et al. Research on circadian clock genes in common abdominal malignant tumors. Chronobiol Int. 2019;36(7):906\u201318.","journal-title":"Chronobiol Int"},{"key":"2321_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12943-016-0492-8","volume":"15","author":"G Mazzoccoli","year":"2016","unstructured":"Mazzoccoli G, Colangelo T, Panza A, Rubino R, De Cata A, Tiberio C, et al. Deregulated expression of cryptochrome genes in human colorectal cancer. Mol Cancer. 2016;15:6.","journal-title":"Mol Cancer"},{"issue":"12","key":"2321_CR42","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/nsmb1344","volume":"14","author":"S Raghuram","year":"2007","unstructured":"Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol. 2007;14(12):1207\u201313.","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"2321_CR43","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/jn\/135.8.1995","volume":"135","author":"J de Vogel","year":"2005","unstructured":"de Vogel J, Jonker-Termont DS, Katan MB, van der Meer R. Natural chlorophyll but not chlorophyllin prevents heme-induced cytotoxic and hyperproliferative effects in rat colon. J Nutr. 2005;135(8):1995\u20132000.","journal-title":"J Nutr"},{"issue":"5","key":"2321_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/jnci\/djh047","volume":"96","author":"DH Lee","year":"2004","unstructured":"Lee DH, Anderson KE, Harnack LJ, Folsom AR, Jacobs DR Jr. Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women\u2019s Health Study. J Natl Cancer Inst. 2004;96(5):403\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2321_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.116.013441","volume":"69","author":"A Ballesta","year":"2017","unstructured":"Ballesta A, Innominato PF, Dallmann R, Rand DA, L\u00e9vi FA. Systems chronotherapeutics. Pharmacol Rev. 2017;69(2):161\u201399.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"2321_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.cmet.2019.06.019","volume":"30","author":"CR Cederroth","year":"2019","unstructured":"Cederroth CR, Albrecht U, Bass J, Brown SA, Dyhrfjeld-Johnsen J, Gachon F, et al. Medicine in the fourth dimension. Cell Metab. 2019;30(2):238\u201350.","journal-title":"Cell Metab"},{"issue":"1","key":"2321_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/cncr.11040","volume":"97","author":"MC Mormont","year":"2003","unstructured":"Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003;97(1):155\u201369.","journal-title":"Cancer"},{"issue":"5","key":"2321_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1470-2045(00)00326-0","volume":"2","author":"F L\u00e9vi","year":"2001","unstructured":"L\u00e9vi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2(5):307\u201315.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2321_CR49","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-13-0171","volume":"20","author":"ZL Zeng","year":"2014","unstructured":"Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, et al. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014;20(4):1042\u201352.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2321_CR50","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/jnci\/82.12.1046","volume":"82","author":"JP Caussanel","year":"1990","unstructured":"Caussanel JP, L\u00e9vi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 1990;82(12):1046\u201350.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2321_CR51","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X","volume":"69","author":"F L\u00e9vi","year":"1992","unstructured":"L\u00e9vi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69(4):893\u2013900.","journal-title":"Cancer"},{"key":"2321_CR52","doi-asserted-by":"crossref","unstructured":"Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brumme P, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 1993;29a(9):1280\u20134.","DOI":"10.1016\/0959-8049(93)90073-O"},{"key":"2321_CR53","doi-asserted-by":"crossref","unstructured":"Adler S, Lang S, Langenmayer I, Eibl-Eibesfeldt B, Rump W, Emmerich B, et al. Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial. Cancer. 1994;73(12):2905\u201312.","DOI":"10.1002\/1097-0142(19940615)73:12<2905::AID-CNCR2820731206>3.0.CO;2-J"},{"issue":"2","key":"2321_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/clpt.1994.123","volume":"56","author":"G Metzger","year":"1994","unstructured":"Metzger G, Massari C, Etienne MC, Comisso M, Brienza S, Touitou Y, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther. 1994;56(2):190\u2013201.","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"2321_CR55","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","volume":"86","author":"FA L\u00e9vi","year":"1994","unstructured":"L\u00e9vi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994;86(21):1608\u201317.","journal-title":"J Natl Cancer Inst"},{"issue":"3 Suppl 1","key":"2321_CR56","first-page":"153","volume":"5","author":"F L\u00e9vi","year":"1995","unstructured":"L\u00e9vi F, Soussan A, Adam R, Caussanel JP, Metzger G, Jasmin C, et al. A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. J Infus Chemother. 1995;5(3 Suppl 1):153\u20138.","journal-title":"J Infus Chemother"},{"key":"2321_CR57","doi-asserted-by":"crossref","unstructured":"Garufi C, L\u00e9vi F, Aschelter AM, Pace R, Giunta S, Nistic\u00f2 C, et al. A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients withmetastatic colorectal cancer. Eur J Cancer. 1997;33(10):1566\u201371.","DOI":"10.1016\/S0959-8049(97)00133-0"},{"issue":"9079","key":"2321_CR58","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","volume":"350","author":"F L\u00e9vi","year":"1997","unstructured":"L\u00e9vi F, Zidani R, Misset JL, International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997;350(9079):681\u20136.","journal-title":"Lancet"},{"issue":"12","key":"2321_CR59","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1","volume":"85","author":"F L\u00e9vi","year":"1999","unstructured":"L\u00e9vi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma International Organization for Cancer Chronotherapy. Cancer. 1999;85(12):2532\u201340.","journal-title":"Cancer"},{"issue":"4","key":"2321_CR60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/00001813-199904000-00006","volume":"10","author":"C Focan","year":"1999","unstructured":"Focan C, Levi F, Kreutz F, Focan-Henrard D, Lobelle JP, Adam R, et al. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. Anticancer Drugs. 1999;10(4):385\u201392.","journal-title":"Anticancer Drugs"},{"issue":"2b","key":"2321_CR61","first-page":"1253","volume":"20","author":"C Natoli","year":"2000","unstructured":"Natoli C, Scognamiglio MT, Martino MT, Irtelli L, De Tursi M, Cianchetti E, et al. Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. Anticancer Res. 2000;20(2b):1253\u20136.","journal-title":"Anticancer Res"},{"issue":"8","key":"2321_CR62","first-page":"3038","volume":"6","author":"MC Mormont","year":"2000","unstructured":"Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest\/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6(8):3038\u201345.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2321_CR63","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.2002.20.5.1175","volume":"20","author":"H Cur\u00e9","year":"2002","unstructured":"Cur\u00e9 H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niezgodzki G, Kwiatkowski F, et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol. 2002;20(5):1175\u201381.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2321_CR64","first-page":"235","volume":"3","author":"TJ Price","year":"2004","unstructured":"Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, et al. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004;3(4):235\u201342.","journal-title":"Clin Colorectal Cancer"},{"key":"2321_CR65","doi-asserted-by":"crossref","unstructured":"Focan C, Bury J, Matus G, Graas MP, Kreutz F, Longree L, et al. [Adjuvant chemotherapy for Dukes B2 and C colon cancer combining 5-fluorouracil and folinic acid with or without carboplatin. Feasibility and comparison between standard and chronomodulated deliveries]. Pathologie-biologie. 2005;53(5):281\u20134.","DOI":"10.1016\/j.patbio.2004.12.030"},{"key":"2321_CR66","doi-asserted-by":"crossref","unstructured":"Focan C, Kreutz F, Longr\u00e9e L, Graas MP, Focan-Henrard D, Moeneclaey N, et al. [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. Pathologie-biologie. 2005;53(5):273\u20136.","DOI":"10.1016\/j.patbio.2004.12.029"},{"issue":"5","key":"2321_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.patbio.2004.12.027","volume":"53","author":"C Focan","year":"2005","unstructured":"Focan C, Kreutz F, Graas MP, Longr\u00e9e L, Moeneclaey N, David A, et al. \u00c9tude de faisabilit\u00e9 (Phase I\u2013II) d\u2019une quadruple combinaison associant le 5-fluorouracile, l\u2019acide folinique et le carboplatine \u00e0 de l\u2019irinotecan administr\u00e9s en infusion chronomodul\u00e9e pour le traitement du cancer colorectal avanc\u00e9. Pathol Biol. 2005;53(5):277\u201380.","journal-title":"Pathol Biol"},{"issue":"22","key":"2321_CR68","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2006.06.1440","volume":"24","author":"S Giacchetti","year":"2006","unstructured":"Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006;24(22):3562\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2321_CR69","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1634\/theoncologist.11-10-1072","volume":"11","author":"D Gholam","year":"2006","unstructured":"Gholam D, Giacchetti S, Br\u00e9zault-Bonnet C, Bouchahda M, Hauteville D, Adam R, et al. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist. 2006;11(10):1072\u201380.","journal-title":"Oncologist"},{"issue":"6","key":"2321_CR70","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdn002","volume":"19","author":"C Qvortrup","year":"2008","unstructured":"Qvortrup C, Yilmaz M, Ogreid D, Berglund A, Balteskard L, Ploen J, et al. Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Ann Oncol. 2008;19(6):1154\u20139.","journal-title":"Ann Oncol"},{"issue":"11","key":"2321_CR71","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/0008-5472.CAN-08-4747","volume":"69","author":"PF Innominato","year":"2009","unstructured":"Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009;69(11):4700\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"2321_CR72","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00280-010-1327-8","volume":"67","author":"F L\u00e9vi","year":"2011","unstructured":"L\u00e9vi F, Karabou\u00e9 A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2011;67(2):339\u201348.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2321_CR73","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/07420528.2011.597532","volume":"28","author":"PF Innominato","year":"2011","unstructured":"Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, et al. <article-title update=\"added\">Prediction of survival by neutropenia according to delivery schedule of oxaliplatin\u20135-fluorouracil\u2013leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011;28(7):586\u2013600.","journal-title":"Chronobiol Int"},{"issue":"12","key":"2321_CR74","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1002\/cam4.3056","volume":"9","author":"PF Innominato","year":"2020","unstructured":"Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karabou\u00e9 A, et al. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: randomized multicenter EORTC 05011 trial. Cancer Med. 2020;9(12):4148\u201359.","journal-title":"Cancer Med"},{"issue":"9","key":"2321_CR75","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","volume":"16","author":"M Mackean","year":"1998","unstructured":"Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer. J Clin Oncol. 1998;16(9):2977\u201385.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2321_CR76","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00280-006-0302-x","volume":"59","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B, Schiavon G, Di Seri M, Virz\u00ed V, Spalletta B, et al. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol. 2007;59(5):613\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2321_CR77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-020-02828-6","volume":"37","author":"J Roosendaal","year":"2020","unstructured":"Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, et al. Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Pharm Res. 2020;37(5):89.","journal-title":"Pharm Res"},{"issue":"8","key":"2321_CR78","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2016.0164","volume":"2","author":"CR Marinac","year":"2016","unstructured":"Marinac CR, Nelson SH, Breen CI, Hartman SJ, Natarajan L, Pierce JP, et al. Prolonged Nightly Fasting and Breast Cancer Prognosis. JAMA Oncol. 2016;2(8):1049\u201355.","journal-title":"JAMA Oncol"},{"issue":"5724","key":"2321_CR79","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science.1108750","volume":"308","author":"FW Turek","year":"2005","unstructured":"Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005;308(5724):1043\u20135.","journal-title":"Science"},{"issue":"5","key":"2321_CR80","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2007.09.006","volume":"6","author":"A Kohsaka","year":"2007","unstructured":"Kohsaka A, Laposky AD, Ramsey KM, Estrada C, Joshu C, Kobayashi Y, et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab. 2007;6(5):414\u201321.","journal-title":"Cell Metab"},{"issue":"1","key":"2321_CR81","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/ije\/dyz064","volume":"49","author":"KE Bradbury","year":"2020","unstructured":"Bradbury KE, Murphy N, Key TJ. Diet and colorectal cancer in UK Biobank: a prospective study. Int J Epidemiol. 2020;49(1):246\u201358.","journal-title":"Int J Epidemiol"},{"key":"2321_CR82","doi-asserted-by":"crossref","unstructured":"Shivappa N, Godos J, H\u00e9bert JR, Wirth MD, Piuri G, Speciani AF, et al. Dietary Inflammatory Index and Colorectal Cancer Risk-A Meta-Analysis. Nutrients. 2017;9(9):2072\u20136643.","DOI":"10.3390\/nu9091043"},{"issue":"50","key":"2321_CR83","doi-asserted-by":"publisher","first-page":"21453","DOI":"10.1073\/pnas.0909591106","volume":"106","author":"C Vollmers","year":"2009","unstructured":"Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD, Panda S. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc Natl Acad Sci U S A. 2009;106(50):21453\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2321_CR84","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cmet.2016.06.001","volume":"23","author":"VD Longo","year":"2016","unstructured":"Longo VD, Panda S. Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan. Cell Metab. 2016;23(6):1048\u201359.","journal-title":"Cell Metab"},{"key":"2321_CR85","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.freeradbiomed.2017.11.003","volume":"119","author":"I Heyde","year":"2018","unstructured":"Heyde I, Kiehn JT, Oster H. Mutual influence of sleep and circadian clocks on physiology and cognition. Free Radic Biol Med. 2018;119:8\u201316.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2321_CR86","doi-asserted-by":"publisher","first-page":"11822","DOI":"10.1038\/s41598-021-91275-3","volume":"11","author":"K Papantoniou","year":"2021","unstructured":"Papantoniou K, Casta\u00f1o-Vinyals G, Espinosa A, Turner MC, Mart\u00edn-S\u00e1nchez V, Casabonne D, et al. Sleep duration and napping in relation to colorectal and gastric cancer in the MCC-Spain study. Sci Rep. 2021;11(1):11822.","journal-title":"Sci Rep"},{"issue":"6","key":"2321_CR87","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/01.mcp.0000183062.98665.6b","volume":"11","author":"F Kapsimalis","year":"2005","unstructured":"Kapsimalis F, Richardson G, Opp MR, Kryger M. Cytokines and normal sleep. Curr Opin Pulm Med. 2005;11(6):481\u20134.","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"2321_CR88","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/1055-9965.EPI-22-0808","volume":"32","author":"LE Barber","year":"2023","unstructured":"Barber LE, VoPham T, White LF, Roy HK, Palmer JR, Bertrand KA. Circadian disruption and colorectal cancer incidence in Black women. Cancer Epidemiol Biomarkers Prev. 2023;32(7):927\u201335.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2321_CR89","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/BF00233492","volume":"214","author":"Y Uchiyama","year":"1981","unstructured":"Uchiyama Y. Circadian alterations in tubular structures on the outer mitochondrial membrane of rat hepatocytes. Cell Tissue Res. 1981;214(3):519\u201327.","journal-title":"Cell Tissue Res"},{"issue":"4","key":"2321_CR90","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cmet.2015.08.006","volume":"22","author":"D Jacobi","year":"2015","unstructured":"Jacobi D, Liu S, Burkewitz K, Kory N, Knudsen NH, Alexander RK, et al. Hepatic Bmal1 Regulates Rhythmic Mitochondrial Dynamics and Promotes Metabolic Fitness. Cell Metab. 2015;22(4):709\u201320.","journal-title":"Cell Metab"},{"issue":"2","key":"2321_CR91","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cmet.2011.01.006","volume":"13","author":"G Asher","year":"2011","unstructured":"Asher G, Schibler U. Crosstalk between components of circadian and metabolic cycles in mammals. Cell Metab. 2011;13(2):125\u201337.","journal-title":"Cell Metab"},{"issue":"12","key":"2321_CR92","doi-asserted-by":"publisher","first-page":"E1673","DOI":"10.1073\/pnas.1519650113","volume":"113","author":"A Neufeld-Cohen","year":"2016","unstructured":"Neufeld-Cohen A, Robles MS, Aviram R, Manella G, Adamovich Y, Ladeuix B, et al. Circadian control of oscillations in mitochondrial rate-limiting enzymes and nutrient utilization by PERIOD proteins. Proc Natl Acad Sci U S A. 2016;113(12):E1673\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5529","key":"2321_CR93","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1126\/science.1060698","volume":"293","author":"J Rutter","year":"2001","unstructured":"Rutter J, Reick M, Wu LC, McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science. 2001;293(5529):510\u20134.","journal-title":"Science"},{"issue":"3","key":"2321_CR94","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2018.01.011","volume":"27","author":"K Schmitt","year":"2018","unstructured":"Schmitt K, Grimm A, Dallmann R, Oettinghaus B, Restelli LM, Witzig M, et al. Circadian Control of DRP1 Activity Regulates Mitochondrial Dynamics and Bioenergetics. Cell Metab. 2018;27(3):657-66.e5.","journal-title":"Cell Metab"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-026-02321-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:04:24Z","timestamp":1779357864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12920-026-02321-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2321"],"URL":"https:\/\/doi.org\/10.1186\/s12920-026-02321-w","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}